Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › PCR › Addressing Coronavirus Testing Bottleneck, Scientists Turn to RNA-Extraction-Free PCR

Addressing Coronavirus Testing Bottleneck, Scientists Turn to RNA-Extraction-Free PCR

Apr 20, 2020
|
Julia Karow

NEW YORK – Two months into the COVID-19 pandemic, the number of SARS-CoV-2 molecular diagnostic tests across the US remains woefully inadequate.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

Feb
26
Featured Webinar

Responding to Emerging SARS-CoV-2 Variants: The Impact on Existing Diagnostic Testing and the Clinical Utility of Differentiation Assays

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.  

What's Popular?

In PCR

  1. CDC Study Finds Abbott BinaxNow SARS-CoV-2 Antigen Test Less Sensitive Than PCR, But Still Useful

  2. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  3. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

  4. Lucira Health Files for $115M IPO

  5. Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.